The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence

Inclusion Criteria: * The subjects who will undergo nephroureterectomy due to ureter or renal pelvis urothelial carcinoma * Male or female aged 18 or over 18 years and not more than 85 years who were diagnosed as upper urinary tract urothelial carcinoma * Normal bone marrow function: Hemoglobin \>10 g/dL, ANC \>1,500/mm3, platelet count\>100,000/mm3 * Normal bladder volume and function * Normal liver function: * Bilirubin ≤ 1.5 times of upper normal limit * AST/ALT ≤ 1.8 times of upper normal limit * Alkaline phosphatase ≤ 1.8 times of upper normal limit * Subjects who voluntarily decided to participate and signed the written informed consent Exclusion Criteria: * Concomitant bladder cancer * Subjects who underwent any treatment due to bladder cancer within 3 years * Prior hypersensitivity reaction history to gemcitabine * Neurogenic bladder * Subjects who underwent chemotherapy due to any cancer within 6 months * Subjects who underwent neoadjuvant chemotherapy due to ureter or renal pelvis urothelial carcinoma * Hypersensitivity to gemcitabine or component of gemcitabine * In case of co-administration of gemcitabine and cisplatin in severe renal failure patients * Moderate to severe liver dysfunction or renal dysfunction (Glomerular filtration rate \< 30 mL/min) * Severe bone marrow suppression * Severe infection * Female who are pregnant or has a possibility of pregnancy * Nursing female * Interstitial pneumonia or pulmonary fibrosis which is evident on chest x-ray and symptomatic * Subjects who are undergoing radiotherapy on chest